Investors had been banking on the study results being the next big driver of the company's shares.
That's due to high demand and after Novo raised its profit outlook in April, said Berenberg analyst Kerry Holford.
If the risk reduction was between 10 and 14%, shares would decrease by less than 5%.
A year ago, investors said a risk reduction of 10 to 14% in the trial would put significant downward pressure on the stock, Holford said.
Barclays analyst Emily Field said a risk reduction as low as 11% could boost the stock.
Persons:
Novo, Kerry Holford, Holford, Emily Field, Maggie Fick, Josephine Mason, Alexandra Hudson
Organizations:
Soaring U.S, Novo Nordisk's, Nestle, UBS, Reuters, Barclays, May, BMO Global Asset Management, Alexandra Hudson Our, Thomson
Locations:
Danish, United States